Sunshine Biopharma Inc
SBFM1.310USD
0.000
收盘 12/24, 13:00（美东）报价延迟15分钟
5.97M总市值
0.25市盈率 TTM
关于 Sunshine Biopharma Inc 公司
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Sunshine Biopharma Inc简介
公司代码SBFM
公司名称Sunshine Biopharma Inc
上市日期Aug 15, 2008
CEOSlilaty (Steve N)
员工数量52
证券类型Ordinary Share
年结日Aug 15
公司地址333 Las Olas Way
城市FORT LAUDERDALE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编33301
电话19543300684
网址https://www.sunshinebiopharma.com/
公司代码SBFM
上市日期Aug 15, 2008
CEOSlilaty (Steve N)
Sunshine Biopharma Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
61.00
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
60.00
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Operating Officer, Director
Chief Operating Officer, Director
59.00
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
1.00
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
Mr. David Natan
Mr. David Natan
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
61.00
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
60.00
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Operating Officer, Director
Chief Operating Officer, Director
59.00
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
1.00
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月20日 周四
更新时间: 11月20日 周四
持股股东
股东类型
持股股东
持股股东
占比
L1 Global Manager Pty Limited
2.90%
Citadel Advisors LLC
1.59%
Renaissance Technologies LLC
1.14%
DRW Securities, LLC
0.92%
Two Sigma Investments, LP
0.79%
其他
92.67%
持股股东
持股股东
占比
L1 Global Manager Pty Limited
2.90%
Citadel Advisors LLC
1.59%
Renaissance Technologies LLC
1.14%
DRW Securities, LLC
0.92%
Two Sigma Investments, LP
0.79%
其他
92.67%
股东类型
持股股东
占比
Investment Advisor
3.90%
Hedge Fund
3.51%
Research Firm
0.10%
Individual Investor
0.04%
其他
92.44%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
33
128.14K
2.61%
-276.56K
2025Q2
40
174.71K
3.84%
-217.75K
2025Q1
40
223.71K
4.97%
+181.45K
2024Q4
39
166.72K
8.34%
+112.42K
2024Q3
38
41.53K
13.09%
+24.77K
2024Q2
37
17.39K
14.86%
+11.35K
2024Q1
40
9.43K
19.69%
+5.56K
2023Q4
38
3.43K
26.72%
+270.00
2023Q3
34
2.71K
21.06%
-1.08K
2023Q2
34
3.32K
29.59%
+626.00
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Citadel Advisors LLC
63.43K
1.39%
+63.43K
--
Jun 30, 2025
Renaissance Technologies LLC
54.09K
1.19%
+54.09K
--
Jun 30, 2025
SBI Securities Co., Ltd.
6.69K
0.15%
+1.47K
+28.16%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
3.83K
0.08%
--
--
Jun 30, 2025
Chamoun (Malek)
1.85K
0.04%
--
--
Apr 01, 2025
UBS Financial Services, Inc.
206.00
0%
-19.68K
-98.96%
Jun 30, 2025
Osaic Holdings, Inc.
152.00
0%
+150.00
+7500.00%
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
公告日期
类型
比率
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
常见问题
Sunshine Biopharma Inc的前五大股东是谁？
Sunshine Biopharma Inc 的前五大股东如下：
Citadel Advisors LLC持有股份：63.43K，占总股份比例：1.39%。
Renaissance Technologies LLC持有股份：54.09K，占总股份比例：1.19%。
SBI Securities Co., Ltd.持有股份：6.69K，占总股份比例：0.15%。
Morgan Stanley Smith Barney LLC持有股份：3.83K，占总股份比例：0.08%。
Chamoun (Malek)持有股份：1.85K，占总股份比例：0.04%。
Citadel Advisors LLC持有股份：63.43K，占总股份比例：1.39%。
Renaissance Technologies LLC持有股份：54.09K，占总股份比例：1.19%。
SBI Securities Co., Ltd.持有股份：6.69K，占总股份比例：0.15%。
Morgan Stanley Smith Barney LLC持有股份：3.83K，占总股份比例：0.08%。
Chamoun (Malek)持有股份：1.85K，占总股份比例：0.04%。
Sunshine Biopharma Inc的前三大股东类型是什么？
Sunshine Biopharma Inc 的前三大股东类型分别是：
L1 Global Manager Pty Limited
Citadel Advisors LLC
Renaissance Technologies LLC
L1 Global Manager Pty Limited
Citadel Advisors LLC
Renaissance Technologies LLC
有多少机构持有Sunshine Biopharma Inc(SBFM)的股份？
截至2025Q3，共有33家机构持有Sunshine Biopharma Inc的股份，合计持有的股份价值约为128.14K，占公司总股份的2.61%。与2025Q2相比，机构持股有所增加，增幅为-1.22%。
哪个业务部门对Sunshine Biopharma Inc的收入贡献最大？
在--，--业务部门对Sunshine Biopharma Inc的收入贡献最大，创收--，占总收入的--%。
